BACKGROUND: The metabolic syndrome is a growing global public health problem. OBJECTIVE: To evaluate the prevalence rate and modal subcomponents of the metabolic syndrome in subjects treated at the West Los Angeles Veterans Administration Medical Center Bipolar Clinic. METHODS: In this cross-sectional design study, using the National Cholesterol Education Program definition, metabolic syndrome prevalence rates were calculated. RESULTS: 48/98 (49%) of subjects met criteria for metabolic syndrome. There was no difference in prevalence rate by gender or race. Almost 70% of the cohort met criteria for metabolic syndrome by the components of reduced HDL and increased waist circumference. Treatment with carbamazepine at study entry was associated with a lower prevalence rate of metabolic syndrome. LIMITATIONS AND CONCLUSIONS: This study is limited by its small size and non-structured assessment of Axis I diagnosis. Nonetheless, bipolar patients in this select cohort have high rates of metabolic syndrome; given this cardiovascular risk, close clinical monitoring for these parameters is recommended. While not controlling for genetics, environmental influences, and/or medical factors such as additional comorbidity and treatment duration, psychotropic drug use may confer differential risk for developing the metabolic syndrome.
BACKGROUND: The metabolic syndrome is a growing global public health problem. OBJECTIVE: To evaluate the prevalence rate and modal subcomponents of the metabolic syndrome in subjects treated at the West Los Angeles Veterans Administration Medical Center Bipolar Clinic. METHODS: In this cross-sectional design study, using the National Cholesterol Education Program definition, metabolic syndrome prevalence rates were calculated. RESULTS: 48/98 (49%) of subjects met criteria for metabolic syndrome. There was no difference in prevalence rate by gender or race. Almost 70% of the cohort met criteria for metabolic syndrome by the components of reduced HDL and increased waist circumference. Treatment with carbamazepine at study entry was associated with a lower prevalence rate of metabolic syndrome. LIMITATIONS AND CONCLUSIONS: This study is limited by its small size and non-structured assessment of Axis I diagnosis. Nonetheless, bipolarpatients in this select cohort have high rates of metabolic syndrome; given this cardiovascular risk, close clinical monitoring for these parameters is recommended. While not controlling for genetics, environmental influences, and/or medical factors such as additional comorbidity and treatment duration, psychotropic drug use may confer differential risk for developing the metabolic syndrome.
Authors: Hua Jin; David Folsom; Alana Sasaki; Sunder Mudaliar; Robert Henry; Monique Torres; Shah Golshan; Danielle K Glorioso; Dilip Jeste Journal: Schizophr Res Date: 2010-11-19 Impact factor: 4.939
Authors: Christine Li; Boris Birmaher; Brian Rooks; Mary Kay Gill; Heather Hower; David A Axelson; Daniel P Dickstein; Tina R Goldstein; Fangzi Liao; Shirley Yen; Jeffrey Hunt; Satish Iyengar; Neal D Ryan; Michael A Strober; Martin B Keller; Benjamin I Goldstein Journal: J Clin Psychiatry Date: 2019-07-30 Impact factor: 4.384
Authors: Jess G Fiedorowicz; David A Solomon; Jean Endicott; Andrew C Leon; Chunshan Li; John P Rice; William H Coryell Journal: Psychosom Med Date: 2009-06-26 Impact factor: 4.312
Authors: Hua Jin; Nicole M Lanouette; Sunder Mudaliar; Robert Henry; David P Folsom; Srikriskna Khandrika; Danielle K Glorioso; Dilip V Jeste Journal: J Clin Psychopharmacol Date: 2009-06 Impact factor: 3.153